Hepatotoxicity after high-dose intravenous methylprednisolone in multiple sclerosis patients

Area of Science:

• Hepatology
• Pharmacology
• Clinical Medicine

Background:

• Methylprednisolone is a widely used corticosteroid.
• Rare adverse events require careful consideration in clinical practice.

Observation:

• Hepatotoxicity is a rare but significant adverse event associated with methylprednisolone use.
• Identifying patients at risk for this side effect is crucial.

Findings:

• Liver function surveillance, including hepatic enzyme monitoring 15-30 days post-administration, is proposed for at-risk patients.
• Alternative therapeutic options such as ACTH, dexamethasone, or plasma exchange are suggested for these patients.

Implications:

• This approach aims to mitigate the risk of drug-induced liver injury from methylprednisolone.
• Proactive monitoring and alternative treatment strategies can improve patient safety.
• Clinical guidelines may benefit from incorporating these recommendations for methylprednisolone therapy.